지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2022.3
- 수록면
- 228 - 237 (10page)
- DOI
- https://doi.org/10.4111/icu.20210425
이용수
초록· 키워드
오류제보하기
Purpose: The recombinant Bacillus Calmette?Guerin (BCG) containing the streptococcal inhibitor of the complement gene (rBCG-sic) may be more resistant to antimicrobial peptides and improve internalization; therefore, it can enhance the immunotherapeutic effect of the BCG. Here we determined the optimal dose of rBCG-sic and compared its effectiveness with that of BCG.
Materials and Methods: We fabricated a high-throughput 3D-bioprinted bladder cancer-on-a-chip (BCOC) and used it to evaluate the effectiveness of the rBCG-sic in terms of cell viability, cell migration, and cytokine concentrations. Using an orthotopic mouse model, we evaluated its anticancer effect and toxicity via bioluminescence imaging.
Results: T24 cell viability was decreased after treatment with rBCG-sic 30 multiplicities of infection (MOI) versus the same dosage of mock BCG (42.8%±6.4% vs. 75.7%±6.6%, p<0.05). THP-1 cell migration was positively correlated with rBCG-sic concentration (2.42-fold at 30MOI, p<0.01). The interleukin-6 concentration of rBCG-sic 30MOI was significantly higher than that of mock BCG 30MOI (11.2±1.3 pg/mL vs. 6.7±0.6 pg/mL, p<0.05). In the orthotopic bladder cancer mouse model, lower tumor volume was observed in the rBCG-sic 30MOI group than in the BCG 30MOI group after 10 days of treatment (p<0.05).
Conclusions: We concluded that rBCG-sic is a useful tool for overcoming BCG unresponsiveness in non-muscle invasive bladder cancer. Additionally, high-throughput BCOC with a microfluidic system can successfully reflect the bladder cancer microenvironment.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Efficacy of recombinant Bacillus Calmette-Guérin containing dltA in in vivo three-dimensional bio-printed bladder cancer-on-a-chip and ex vivo orthotopic mouse model
Investigative and Clinical Urology
2023 .05
-
Efficacy of Bacillus Calmette-Guérin in Cancer Prevention and Its Putative Mechanisms
대한암예방학회지
2024 .03
-
Antitumor effects of intravesical treatment on bacillus calmette-guerin cell wall cytoskeleton with encapsulated liposome in orthotopic mouse model of bladder cancer
한국실험동물학회 학술발표대회 논문집
2019 .07
-
Low-dose versus standard-dose bacille Calmette?Guerin for non-muscle-invasive bladder cancer: Systematic review and meta-analysis of randomized controlled trials
Investigative and Clinical Urology
2022 .03
-
A possible protective role for Bacillus Calmette-Guérin therapy in urinary bladder cancer in the era of COVID-19: a brief report
Clinical and Experimental Vaccine Research
2021 .01
-
Assessment of immunological markers and booster effects of Ag85B peptides, Ag85B, and BCG in blood of BCG vaccinated children: a preliminary report
Clinical and Experimental Vaccine Research
2016 .01
-
Severity of COVID-19 in bacillus Calmette-Guerin vaccinated population
Clinical and Experimental Vaccine Research
2021 .09
-
Rates and Risk Factors of Bacteriuria in Patients with Bladder Cancer Who Underwent Treatment with Bacillus Calmette-Guerin
Urogenital Tract Infection
2020 .01
-
Emerging treatments for bacillus Calmette–Guérin-unresponsive non-muscle-invasive bladder cancer
Investigative and Clinical Urology
2021 .01
-
Comparative analysis of recurrence rates between intravesical gemcitabine and bacillus Calmette–Guérin induction therapy following transurethral resection of bladder tumors in patients with intermediate- and high-risk bladder cancer: A retrospective multicenter study
Investigative and Clinical Urology
2024 .05
-
Role of oral pentosan polysulfate in Bacillus Calmette?Guerin therapy in patients with non-muscle-invasive bladder cancer
Investigative and Clinical Urology
2022 .09
-
Bacille Calmette-Guérin (BCG) 백신 접종 후림프절염의 발생 빈도
Pediatric Infection and Vaccine
2016 .01
-
Feasibility of Photodynamic Diagnosis for Challenging TUR-Bt Cases Including Muscle Invasive Bladder Cancer, BCG Failure or 2<sup>nd</sup>-TUR
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Symptoms of Bacillus Calmette-Guerin Cystitis in Bladder Cancer Patients according to Tuberculosis Sequelae by Chest Radiography
Urogenital Tract Infection
2017 .01
-
Granulomatous Prostatitis After Intravesical Bacillus Calmette-Guérin Instillation Therapy: A Potential Cause of Incidental F-18 FDG Uptake in the Prostate Gland on F-18 FDG PET/CT in Patients with Bladder Cancer
Nuclear medicine and molecular imaging : NMMI
2016 .01
-
Seminal Vesicle Involvement by Carcinoma In Situ of the Bladder: Clonal Analysis Using Next-Generation Sequencing to Elucidate the Mechanism of Tumor Spread
Cancer Research and Treatment
2020 .01
-
Tuberculous Spondylitis after Intrarenal Bacille Calmette-Guerin (BCG) Therapy
전남의대학술지
2019 .01
-
Predictors and outcomes of sepsis-induced cardiomyopathy in critically ill patients
Acute and Critical Care
2020 .01
-
Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer: Abridged summary of the Cochrane Review
Investigative and Clinical Urology
2020 .01
-
OK-432 Suppresses Proliferation and Metastasis by Tumor Associated Macrophages in Bladder Cancer
Asian Pacific journal of cancer prevention : APJCP
2015 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0